Thirteen years after 11 March 2013 — the date the EU Cosmetics Regulation's full marketing ban on animal-tested products took effect — Cruelty Free International has published a report titled "Animals still die in the name of beauty – 13 years after EU cosmetics testing bans," arguing that the regulatory promise of 2013 has not been matched in practice.

What does "13 years after the ban" actually reference?

Regulation (EC) 1223/2009 phased in two distinct prohibitions. The first banned animal testing of finished cosmetic products (effective 2004) and of cosmetic ingredients (for most endpoints from March 2009). The second, the marketing ban under Article 18, took full effect on 11 March 2013, barring the placement on the EU market of any cosmetic whose ingredients or finished product were tested on animals in order to satisfy the Regulation. Thirteen years on, Cruelty Free International's framing centers on what the marketing ban does not cover.

Which structural gaps does the report flag?

Three pressure points consistently appear in the organization's analysis of where the 2013 framework leaks.

• Legacy safety data. Substances with toxicity profiles built on pre-2004 vertebrate studies remain in commerce. Where that historical dossier is the only available one, brands face a regulatory grey zone between inherited compliance and Article 18 obligations.
• REACH dual-use overlap. REACH registration dossiers on substances also used in cosmetics can still require new vertebrate assays (repeated-dose toxicity, reproductive toxicity, ecotoxicity). Cosmetic-grade substances are therefore exposed to in vivo testing generated under chemicals law, not cosmetics law.
• Third-country testing. Animal testing commissioned outside the EU to satisfy non-EU regulators — most visibly China's NMPA, historically the largest single trigger — falls outside Article 18's territorial scope and remains a documented flashpoint for NGO campaigns.

What does this change for compliance teams today?

For regulatory affairs managers, formulators and procurement leads, the report's publication raises operational pressure in three workflows.

• Supplier declarations. Confirm whether each INCI ingredient's safety dossier relies on post-2009 OECD Test Guidelines vertebrate data. Where it does, finished product placement in the EU is on collision course with Article 18.
• Cross-regulation mapping. Cross-check cosmetic-grade substances against REACH Annex XVII listings, SVHC candidate lists, and any dossiers under evaluation by ECHA. Substances under ECHA review can pull cosmetic use into new vertebrate testing obligations.
• Third-country alignment. Map ingredient supply chains against the regulatory requirements of destination markets. Cruelty Free International's continued scrutiny raises the probability that NGO campaigns will surface supply-chain audits involving China, India and parts of Southeast Asia — categories where finished-product testing has historically been required.

What is the next regulatory data point to watch?

Watch the next SCCS Notes of Guidance revisions, scheduled through 2026–2027, for explicit validation criteria for New Approach Methodologies (NAMs) — organs-on-chips, QSAR models, read-across frameworks — as standalone replacements for in vivo endpoints. The Commission's working documents on the interaction between the Cosmetics Regulation and the ongoing REACH revision will indicate whether the REACH-side loophole narrows, and a finalized Commission position on cross-jurisdictional NAMs acceptance versus third-country regulators — particularly NMPA — will be the next concrete test of whether the 2013 promise closes in practice.